Resumen

SANCHEZ-GARCIA, C; BAILON-ORTEGA, AA  y  ZALTZMAN-GIRSHEVICH, S. Statins treatment in pediatric patients with steroid resistant nephrotic syndrome. A two case reports. Acta pediatr. Méx [online]. 2017, vol.38, n.1, pp.26-32. ISSN 2395-8235.  https://doi.org/10.18233/apm1no1pp26-321321.

The nephrotic syndrome is defined by the association of proteinuria, hypoalbuminemia, hyperlipidemia and edema. 80% of the pediatric patients with primary nephrotic syndrome respond to steroid therapy; the remaining 20% require associate other drugs to achieve remission (cyclophosphamide, cyclosporine). The hyperlipidemia in the nephrotic syndrome is due both to an increased synthesis and decreased elimination of blood lipids; being the direct cause of this the proteinuria. The hyperlipidemia increases cardiovascular risk and glomerular damage. Based on this, the persistent hyperlipidemia in the steroid-resistant nephrotic syndrome should be treated. The HMG-CoA reductase inhibitors have shown immunomodulatory, anti-inflammatory and anti-proliferative effect. Therefore, the role of statins in the nephrotic syndrome goes beyond their lipid-lowering effect.

We present two cases of pediatric patients diagnosed with steroid-resistant nephrotic syndrome and its evolution during treatment with cyclosporine and statins.

Palabras llave : proteinuria; statins; nephrotic syndrome; hyperlipidemia.